Vacca A, Ribatti D, Ria R, Pellegrino A, Bruno M, Merchionne F, Dammacco F
Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Italy.
Dev Immunol. 2000;7(2-4):77-88. doi: 10.1155/2000/74372.
Matrix metalloproteinase (MMP) expression and production are associated with advanced-stage tumor and contribute to tumor progression, invasion and metastases. The current study was designed to determine the expression and production of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by human lymphoid tumor cells. Changes in expression and production were also investigated during tumor progression of multiple myeloma and mycosis fungoides. In situ hybridization analysis revealed that lymphoblastic leukemia B cells (SB cell line), multiple myeloma (MM) cells (U266 cell line) and lymphoblastic leukemia T cells (CEM and Jurkat cell lines) express constitutively the mRNA for MMP-2 and/or MMP-9. We demonstrated by gelatin-zymography of cell culture medium that both enzymes were secreted in their cleaved (activated) form. In situ hybridization of bone marrow plasma cells and gelatin-zymography of the medium showed that patients with active MM (diagnosis, relapse, leukemic progression) express higher levels of MMP-2 mRNA and protein than patients with non-active MM (complete/objective response, plateau) and with monoclonal gammopathies of undetermined significance (MGUS). MMP-9 expression and secretion was similar in all patient groups. In patients with mycosis fungoides (MF), the expression of MMP-2 and MMP-9 mRNAs was significantly upregulated with advancing stage, in terms of lesions both positive for one of two mRNAs and with the greatest intensity of expression. Besides MF cells, the MMP-2 and/or MMP-9 mRNAs were expressed by some stromal cell populations (microvascular endothelial cells, fibroblasts, macrophages), suggesting that these cells cooperate in the process of tumor invasion. Our studies identify MMPs as an important class of proteinases involved in the extracellular matrix (ECM) degradation by human lymphoid tumors, and suggest that MMPs inhibitors may lead to important new treatment for their control.
基质金属蛋白酶(MMP)的表达和产生与晚期肿瘤相关,并促进肿瘤进展、侵袭和转移。本研究旨在确定人淋巴肿瘤细胞中MMP-2(明胶酶A)和MMP-9(明胶酶B)的表达和产生情况。还研究了多发性骨髓瘤和蕈样肉芽肿肿瘤进展过程中表达和产生的变化。原位杂交分析显示,B淋巴细胞白血病细胞(SB细胞系)、多发性骨髓瘤(MM)细胞(U266细胞系)和T淋巴细胞白血病细胞(CEM和Jurkat细胞系)组成性表达MMP-2和/或MMP-9的mRNA。我们通过细胞培养基的明胶酶谱分析证明,这两种酶均以裂解(活化)形式分泌。骨髓浆细胞的原位杂交和培养基的明胶酶谱分析表明,活动性MM患者(诊断、复发、白血病进展)比非活动性MM患者(完全/客观缓解、平台期)和意义未明的单克隆丙种球蛋白病(MGUS)患者表达更高水平的MMP-2 mRNA和蛋白。所有患者组中MMP-9的表达和分泌情况相似。在蕈样肉芽肿(MF)患者中,MMP-2和MMP-9 mRNA的表达随着病情进展而显著上调,就两种mRNA之一呈阳性且表达强度最大的病变而言。除了MF细胞外,一些基质细胞群体(微血管内皮细胞、成纤维细胞、巨噬细胞)也表达MMP-2和/或MMP-9 mRNA,提示这些细胞在肿瘤侵袭过程中协同作用。我们的研究确定MMPs是参与人淋巴肿瘤细胞外基质(ECM)降解的一类重要蛋白酶,并提示MMPs抑制剂可能为其控制带来重要的新治疗方法。